Annexon, Inc. Common Stock
ANNXAnnexon, Inc. is a biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases. It specializes in targeting the complement system to address conditions such as Alzheimer’s disease, multiple sclerosis, and other immune-related disorders. The company's approach involves creating monoclonal antibodies that modulate the immune response to prevent cellular damage.
Company News
The GBS|CIDP Foundation International is launching the 'GBS: 110 Years, 110 Stories' campaign to mark 110 years since the discovery of Guillain-Barré syndrome. The campaign will feature 110 patient stories in short videos to raise awareness about GBS and CIDP, rare neurological disorders. The foundation has partnered with Annexon Biosciences to ...
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on targeted immunotherapies for neuroinflammatory diseases, announced that its President and CEO Douglas Love will present at the Bank of America Securities Health Care Conference on May 13, 2026. The company is advancing therapies targeting C1q-driven neuroinflammation, with ARCHE...
Annexon, a biopharmaceutical company, granted a stock option to a new non-executive employee for 19,000 shares with a 4-year vesting schedule and an exercise price of $4.91 per share.
Annexon, a biopharmaceutical company, announced a public offering of 25,096,153 shares of common stock and pre-funded warrants, expecting to raise $75 million to support its neuroinflammation research platform.
Annexon completed enrollment for its Phase 3 ARCHER II trial of vonaprument, a potential treatment for dry age-related macular degeneration with geographic atrophy. The trial aims to demonstrate vision preservation and is expected to report topline data in the second half of 2026.
